Phase 3, Single-center, Sequential and Parallel-group, Double-blind, Randomized Study Evaluating the Efficacy and Safety of Fexofenadine Hydrochloride 180 mg (Allegra/Telfast) Versus Placebo in Subjects Suffering From Seasonal Allergic Rhinitis With Symptoms Aggravated in Presence of Pollutants
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Fexofenadine (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Acronyms FEXPOLSAR
- Sponsors Sanofi
- 29 Jan 2019 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Sep 2018 Status changed from not yet recruiting to recruiting.